Historical ilmn News Stories
Illumina Rally, Guidance Cut & MGI Threat Looms Q4
Illumina shares rose on renewed investor interest even as Q1 results prompted a trimmed full‑year outlook. Strategic partnerships in single‑cell and clinical sequencing, plus board appointments, offer offsets to headwinds from China restrictions and intensified competition from MGI’s new ultrafast sequencer. Investors should weigh short‑term sentiment against structural risks and execution catalysts.
Roche’s Speed Threat & Illumina’s Counterplay 2025
Roche’s new ultra-fast SBX sequencing and upcoming Axelios instrument have intensified competition with Illumina, while Illumina doubles down with Constellation mapped reads and a Perturb‑seq single-cell solution. Near-term pressures include China trade restrictions and soft guidance, but product innovation and strategic partnerships could determine ILMN’s trajectory.
Illumina Rises After WGS Nature Study, DRAGEN Win!
Illumina shares climbed on renewed investor interest after a Nature-backed whole-genome sequencing (WGS) study — run using Illumina's DRAGEN pipeline — demonstrated far greater capture of heritability across 34 complex traits than exomes or genotyping arrays. Short-term price gains this past week reflect market momentum, while the study reinforces Illumina's long-term technology moat and potential for expanded clinical and research uptake.
Illumina Q3 Beat, Guidance Hike; Analyst Split Now
Illumina reported a Q3 beat, raised FY guidance and reported 55 NovaSeq X placements, prompting a short-term stock pop but mixed analyst reaction—Barclays remains cautious. Here’s a concise, data-driven take on what moved ILMN this week and what investors should watch next.
Illumina Analyst Targets Rise to $115; Why? Update
Analysts nudged Illumina (ILMN) price targets higher this week—TD Cowen to $115, Canaccord to $112, Stephens $110 and JPMorgan $105—reflecting modestly improved sentiment. No new corporate events were reported; the shift centers on financial expectations and execution. This article summarizes the changes, explains why they matter for investors, outlines near-term catalysts and key risks, and suggests practical steps for those watching ILMN in the Nasdaq-100.
Illumina Surges After Q3 Beat, SomaLogic Deal Now!
Illumina (ILMN) jumped after a Q3 earnings beat and improved guidance, driven by a rebound in its clinical sequencing business and the announced SomaLogic acquisition. Investors should watch integration of proteomics capabilities, China exposure, cost cuts and upcoming quarterly confirmations.